Premium
Selection and characterization of novel DNA aptamer against colorectal carcinoma Caco‐2 cells
Author(s) -
Maimaitiyiming Yasen,
Yang Chang,
Wang Yun,
Hussain Liaqat,
Naranmandura Hua
Publication year - 2019
Publication title -
biotechnology and applied biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 70
eISSN - 1470-8744
pISSN - 0885-4513
DOI - 10.1002/bab.1737
Subject(s) - aptamer , systematic evolution of ligands by exponential enrichment , hela , colorectal cancer , oligonucleotide , dna , hek 293 cells , nucleic acid , microbiology and biotechnology , biology , rna , caco 2 , negative selection , in vitro , chemistry , computational biology , cell culture , biochemistry , cancer , genetics , gene , genome
Aptamers are short, single‐stranded nucleic acid (DNA or RNA) oligonucleotides that can be obtained by a technique called systematic evolution of ligands by exponential enrichment (SELEX) in vitro . Due to superior properties such as small size, high binding affinity, and stability, they are considered to be feasible tools for diagnosis and treatment of disease. In the current study, we attempted to screen a high‐affinity DNA aptamer to selectively target the colorectal carcinoma Caco‐2 cells by using cell‐based SELEX approach. After 14 consecutive rounds of selection, aptamer ApC1 was identified. Confocal microscopy results revealed that ApC1 could rapidly internalize into Caco‐2 cells but not HEK 293 cells. Moreover, it showed high specificity to Caco‐2 cells rather than other cell lines such as 293T, HeLa, MCF‐7, HL‐60, and NB4. Collectively, our results demonstrated that aptamer ApC1 has high specificity to colorectal carcinoma Caco‐2 cells, which could be further applied for targeted therapy of colorectal cancer in future studies.